- Home
- CMND vs TCRT Comparison
CMND vs TCRT Comparison
Compare CMND & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMND | TCRT |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.4M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CMND | TCRT |
|---|---|---|
| Price | $6.43 | $2.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 49.4K | ★ 11.9M |
| Earning Date | 09-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.72 |
| 52 Week High | $7.16 | $4.50 |
Technical Indicators
Market Signals| Indicator | CMND | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 81.01 | 68.53 |
| Support Level | $0.65 | $2.17 |
| Resistance Level | $7.16 | $3.25 |
| Average True Range (ATR) | 0.46 | 0.59 |
| MACD | 0.22 | 0.24 |
| Stochastic Oscillator | 86.21 | 58.98 |
Price Performance
Historical ComparisonAbout CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.